Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
$1,318.00
Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a rare blood cancer characterized by rapid proliferation and accumulation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.
- Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
- Industry-sponsored drugs in active clinical development for ALL are spread evenly across Phase I and Phase II, with two drugs in Phase III.
- Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.
- High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, an expected BLA filing for Tecartus, and an estimated European supplemental approval decision for Blincyto.
- The overall likelihood of approval of a Phase I hematologic asset is 9.5%, and the average probability a drug advances from Phase III is 60.3%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.5 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I–II, and only 8% in Phase III–IV.
- The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the ALL space is dominated by completed trials. Novartis has the highest number of completed clinical trials for ALL, with 45 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Chemotherapy
11 Corticosteroids
11 TKI therapy
11 Immunotherapy
12 Radiation therapy
12 Stem cell transplant
13 EPIDEMIOLOGY
16 MARKETED DRUGS
20 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Blincyto for ALL (December 10, 2019)
29 GC022 for ALL (December 7, 2019)
30 Blincyto for ALL (September 24, 2019)
31 Copiktra for ALL (July 25, 2019)
32 Tecartus for ALL (June 1, 2019)
35 KEY UPCOMING EVENTS
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 IO-Focused CoImmune, Formula Merge In All-Stock Deal
37 Pascal, Y-Biologics Ink Bispecific Collaboration For Leukemia
38 REVENUE OPPORTUNITY
40 CLINICAL TRIAL LANDSCAPE
41 Sponsors by status
42 Sponsors by phase
44 BIBLIOGRAPHY
45 Prescription information
46 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of ALL, 2018–27
20 Figure 2: Overview of pipeline drugs for ALL in the US
20 Figure 3: Pipeline drugs for ALL, by company
21 Figure 4: Pipeline drugs for ALL, by drug type
21 Figure 5: Pipeline drugs for ALL, by classification
31 Figure 6: Blincyto for ALL (September 24, 2019): Phase III – Pediatric (1st Relapse)
34 Figure 7: Tecartus for ALL (June 1, 2019): Phase I/II – ZUMA-3 (r/r Adults)
35 Figure 8: Key upcoming events in ALL
36 Figure 9: Probability of success in the hematologic pipeline
40 Figure 10: Clinical trials in ALL
40 Figure 11: Top 10 drugs for clinical trials in ALL
41 Figure 12: Top 10 companies for clinical trials in ALL
41 Figure 13: Trial locations in ALL
42 Figure 14: ALL trials status
43 Figure 15: ALL trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of ALL, 2018–27
17 Table 2: Marketed drugs for ALL
22 Table 3: Pipeline drugs for ALL in the US
28 Table 4: Blincyto for ALL (December 10, 2019)
29 Table 5: GC022 for ALL (December 7, 2019)
30 Table 6: Blincyto for ALL (September 24, 2019)
32 Table 7: Copiktra for ALL (July 25, 2019)
33 Table 8: Tecartus for ALL (June 1, 2019)
38 Table 9: Historical global sales, by drug ($m), 2015–19
39 Table 10: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Small-Cell Lung Cancer (SCLC) 
Sign up to the